ReviewAntibiotics (Basel, Switzerland)2025
New Antibiotics for Treating Infections Caused by Multidrug-Resistant Bacteria.
Review in Antibiotics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Eravacycline as a Novel Option for Treating Multidrug-Resistant Gram-Negative and Gram-Positive Bacterial Infections: A Narrative Review.Journal of clinical medicine · 2026Review
- Article
- Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations.Microorganisms · 2026Review
- Burn Infections and Sepsis: Challenges and Future Prospects of Antibacterial Therapy.Antibiotics (Basel, Switzerland) · 2026Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections caused by antibiotic resistant bacteria pose a serious threat to global health, leading to higher medical costs, longer hospital stays, and increased morbidity and mortality. An increasing number of bacteria have been implicated in untreatable infections due to multiple resistance mechanisms. In 2017, the World Health Organization published a list of the most important antibiotic resistant bacteria worldwide, for which there is an urgent need to develop new therapeutic options. In recent years, fortunately, new antibiotics have been approved for the treatment of infections caused by multidrug-resistant bacteria. The purpose of this review is to present the most impactful new antibiotics that are currently available for the treatment of these infections. The discovery of new therapeutic strategies will help to limit the spread of multidrug-resistant bacteria, but careful prescribing, appropriate use and monitoring of resistant strains will be crucial to ensure that they remain effective in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.